Merck’s 60% price cut for hepatitis C drug nets company a big sales opportunity

Merck & Co.’s plans to slash the price of its hepatitis C medication, announced just weeks ago, reaped a tangible reward on Tuesday.

The drug, Zepatier, will be considered a preferred product by the large pharmacy-benefit manager Express Scripts Holding Company starting next year, marking a change to this year’s list of covered drugs.